Karuna Therapeutics announced that it has commenced an underwritten public offering of $400M of its common stock. Goldman Sachs & Co., J.P. Morgan Securities, and Morgan Stanley & Co. are acting as joint book-running managers for the offering.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on KRTX:
- Karuna Therapeutics Down Even after Positive Topline Results
- Karuna Therapeutics announces ‘positive’ results from Phase 3 EMERGENT-3 trial
- Sell these stocks now, proven algorithm says
- Karuna says maintains ‘de minimis amount’ of cash, equivalents with SVB
- Karuna initiated with Neutral, $214 target at Cantor Fitzgerald